published_or_final_version / abstract / Medicine / Master / Master of Philosophy

published_or_final_version / Clinical Oncology / Doctoral / Doctor of Philosophy

No description available.

No description available.

Patients receiving Intensity Modulated Radiation Therapy (IMRT) for late stage head and neck (HN) cancer often experience anatomical changes due to weight loss, tumor regression, and positional changes of normal anatomy (1). As a result, the actual dose delivered may vary from the original treatment plan. The purpose of this study was (a) to evaluate the dosimetric consequences of the parotid glands during the course of treatment, and (b) to determine if there would be an optimal timeframe for replanning. Nineteen locally advanced HN cancer patients underwent definitive IMRT. Each patient received an initial computerized tomography simulation (CT-SIM) scan and weekly cone beam computerized tomography (CBCT) scans. A Deformable Image Registration (DIR) was performed between the CT-SIM and CBCT of the parotid glands and Planning Target Volumes (PTVs) using the Eclipse treatment planning system (TPS) and the Velocity deformation software. A recalculation of the dose was performed on the weekly CBCTs using the original monitor units. The parameters for evaluation of our method were: the changes in volume of the PTVs and parotid glands, the dose coverage of the PTVs, the lateral displacement in the Center of Mass (COM), the mean dose, and Normal Tissue Complication Probability (NTCP) of the parotid glands. The studies showed a reduction of the volume in the PTVs and parotids, a medial displacement in COM, and alterations of the mean dose to the parotid glands as compared to the initial plans. Differences were observed for the dose volume coverage of the PTVs and NTCP of the parotid gland values between the initial plan and our proposed method utilizing deformable registration-based dose calculations. / Includes bibliography. / Thesis (M.S.)--Florida Atlantic University, 2015. / FAU Electronic Theses and Dissertations Collection

Orientador: Mariângela Esther Alencar Marques / Coorientador: Luciana Abbade / Banca: Renata Aparecida Martinez Antunes Ribeiro Vieira / Banca: Gisele Alborghetti Nai / Resumo: O carcinoma espinocelular (CEC) é tumor maligno das células espinhosas da epiderme caracterizado por evolução mais rápida, maior poder invasivo e metastático em relação ao carcinoma basocelular (CBC). A área mais profunda e infiltrativa do CEC, conhecida como fronte de invasão, revela células neoplásicas malignas com menor grau de diferenciação comparadas à totalidade da lesão. Estudos recentes demonstram a influência do padrão do fronte de invasão tumoral no prognóstico de CEC de laringe e colo uterino. Contudo, não há estudos sobre o mesmo em relação a CEC cutâneos de cabeça e pescoço. Estudar as características clínicas, histopatológicas e perfil imuno-histoquímico do CEC de cabeça e pescoço e fronte de invasão tumoral, correlacionando-o com comportamento biológico. O estudo foi do tipo coorte retrospectivo, sendo selecionados os pacientes que tiveram diagnóstico de CEC de cabeça e pescoço confirmados pelo exame anatomopatológico no período de 1999 a 2009. A avaliação do fronte de invasão tumoral foi realizada empregando-se imuno-histoquímica para E-caderina, ki-67 e p53. Resultados: O tipo de fronte de invasão, bem como as expressões de E-caderina e ki-67, seja em sítio superficial ou profundo, não apresentaram associação com os critérios prognósticos histopatológicos. Os achados mostraram que a E-caderina, o p53 e o ki-67 foram mais expressos em tumores com tamanho ˃ 2cm. Em relação a espessura do tumor, observamos que o p53 foi mais expresso na profundidade nas lesões mais espessas (índice de Breslow maior que 2mm), e que foi acompanhada também pela expressão maior do Ki-67.A expressão de p53 em sítio superficial teve associação inversa com o critério de espessura (p<0,049) e, em sítio profundo, teve associação direta com a intensidade do processo inflamatório local (p<0,046). O tipo de fronte de invasão, bem como as expressões de E-caderina, ki-67 e p53, em sítios ... / Abstract: The Squamous Cell Carcinoma (SCC) is a malignant epidermal tumor of squamous epithelial cells, characterized for greater aggressiveness much higher incidence of metastasis than Basal Cell Carcinoma (BCC). The deepest invading tumor area, known as invasive tumor front usually disclose less differentiated malignant cells, compared with the whole lesion. Recent studies demonstrate the influence of the invasive tumor front pattern on the prognosis of larynx and uterine cervix SCC. However, there is no studies about that on cutaneuos SCC of the head and neck. To study the clinical, histopathological and immunohistochemical profile of the SCC from head and neck and its invasive tumor front, correlating it with its biological behavior. The study was a retrospective type coorte, where the patients with histopathological diagnosis of head and neck cutaneous SCC among 1999 to 2009 were selected. The evaluation of invasive tumor front was immunohistochemistry for E-cadherin, ki-67 and p53. The pattern of invasive tumor front, as well as E-cadherin and ki-67 expressions, at superficial and deep sites, did not present association with histopathological prognostic criteria. The findings showed that E-cadherin, p53 and Ki-67 were more highly expressed in tumors with size ˃ 2cm. Regarding the thickness of the tumor, we observed that p53 was expressed in depth in thicker lesions (Breslow thickness greater than 2 mm), which was also accompanied by higher expression of Ki-67. p53 expression, at superficial site, had inverse association with thickness criteria (p<0,049) and, at deep site, had direct association with local inflammatory process intensity (p<0,046). The invasive tumor front, as well as E-cadherin, ki-67 and p53 expressions, at superficial and deep sites, did not demonstrate impact on free disease survival. The characteristics of invasive tumor front did not correlate with prognosis in cutaneuos SCC of the head and neck regarding to the ... / Mestre

Orientador: Batista de Oliveira Junior / Coorientador: Lídia Raquel de Carvalho / Banca: Joel Castro Lastória / Banca: Renato Yassutaka Faria Yaedú / Resumo: Cada ano, mais de 600.000 casos de câncer de cabeça e pescoço são diagnosticados mundialmente, alguns com prognóstico desfavorável devido ao desenvolvimento de segundos tumores primários nos pulmões, esôfago ou em áreas previamente irradiadas ou operadas. Este estudo tem como objetivo verificar a incidência de segundos tumores primários em pacientes com câncer de cabeça e pescoço num seguimento de 7 anos, identificar o tempo entre o diagnóstico do primeiro tumor e do segundo tumor primário e o tempo de sobrevivência entre diagnóstico inicial e o óbito. Foram utilizados 1061 prontuários de pacientes com neoplasia de cabeça e pescoço do serviço de Registro Hospitalar de Câncer do Hospital Amaral Carvalho de Jaú. Neste estudo, 8,95% dos pacientes com câncer de cabeça e pescoço desenvolveram segundo tumor primário de esôfago e laringe. A maioria dos segundos tumores primários se desenvolveu antes de cinco anos de seguimento, após o diagnóstico do tumor primário. O tempo de vida médio estimado para todos os pacientes avaliados que foram a óbito foi de 1,8 anos / Abstract: Each year, more than 600.000 cases of head and neck cancer are diagnosed worldwide, someone with unfavorable prognosis due to the development of second primary tumors in the lungs, esophagus or in areas previously irradiated or operated. This study aims to determine the incidence of second primary tumors in patients with head and neck cancer in follow up 7 years , identify the time between diagnosis of the first primary and second primary tumor and survival time between initial diagnosis and death. We used medical records of 1061 patients with head and neck cancer service registry Hospital Cancer Hospital Amaral Carvalho de Jaú. In this study, 8.95% of patients with head and neck cancer developed second primary tumor of the esophagus and larynx. Most second primary tumors developed before five years of follow-up after diagnosis of the primary tumor. The average life span estimated for all patients who died was 1.8 years / Mestre

One of the main objectives of combining radiation treatment and chemotherapy is to obtain a therapeutic gain by an improved tumour control with less or no enhancement of normal tissue toxicity. The optimal schedule for the combined treatment of cisplatin-radiation is still under investigation. Neither the optimal time interval, nor the most adequate sequence of administration of cisplatin and radiation are known. The results of the trials are also inconclusive. Some trials showed a supra-additive effect from the administration of cisplatin before radiotherapy, others, on contrary, from the injection of drug after radiotherapy. The present work encompasses the major challenges brought by the combined modality treatment: cisplatin-radiotherapy. The major goal of this work was to investigate the optimal treatment sequencing between cisplatin and radiotherapy and also the optimal schedule for head and neck carcinomas. Therefore, a computer-based tumour model with literature-given biological parameters has been developed which has allowed the simulation of treatment with radiation and chemotherapy. Radiotherapy has been simulated on the virtual tumour and the effects of radiotherapy on tumour regression and regrowth have been analyzed. Also, the mechanisms of cisplatin's action on tumour have been implemented, and the phenomena of drug resistance and tumour repopulation during chemotherapy studied. Finally, the combined modality treatment has been simulated, and the effect of drug-radiation interaction on tumour behaviour evaluated. The current investigation has shown that cisplatin administered immediately before radiation gives similar tumour control to the post-radiation sequencing of the drug. Furthermore, the killing effect of the combined modality treatment on tumour increases with the increase in cell recruitment. The individual cell kill produced by cisplatin and radiation leads to an additive-only tumour response when the treatments are given concurrently, and for a synergistic effect cisplatin must potentiate the effect of radiation. The final conclusion, by which cisplatin administered on a daily basis leads to a better tumour control than cisplatin administered weekly, is in accordance with the latest trial results on head and neck cancers. Therefore, treatment regimens that correlate better with the pharmacokinetics and the radiobiological properties of the therapeutic agents result in better outcomes. / Thesis (Ph.D.)--School of Chemistry and Physics, 2004.

published_or_final_version / Surgery / Master / Master of Philosophy

No description available.